Trial Profile
Efficacy of ezetimibe for the treatment of non-alcoholic fatty liver disease: A randomized, controlled trial
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 23 Feb 2015
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 23 Feb 2015 New trial record